This paper reviews the preclinical and clinical data for ibrutinib when used in the treatment of CLL. Recent studies showing the benefit of combination therapy using ibrutinib, monoclonal antibodies, and chemoimmunotherapy are also discussed.
Ibrutinib: an evidence-based review of its pot... - CLL Support
Ibrutinib: an evidence-based review of its potential in the treatment of advanced chronic lymphocytic leukemia...
Written by
Cllcanada
Top Poster CURE Hero
To view profiles and participate in discussions please or .
Read more about...
Not what you're looking for?
You may also like...
BTK C481S-Mediated Resistance to Ibrutinib in Chronic Lymphocytic Leukemia
It gets kinda technical but this is some great research on ibrutinib resistance by Dr. Woyach....
Ibrutinib Plus Venetoclax in Relapsed/Refractory Chronic Lymphocytic Leukemia: Update on The CLARITY Study
Published on line July 11, 2019, Accepted by JCO May 31 2019
Dr P Hillmen
We have some members who...
Disease Flare During Temporary Interruption of Ibrutinib Therapy in Patients with Chronic Lymphocytic Leukemia ( CLL ) - Pseudo Richters
Several of us have reported our CLL symptoms have come roaring back after discontinuing...
Long-term safety of single-agent ibrutinib in patients with chronic lymphocytic leukemia in 3 pivotal studies
I have checked but apologies if this has been posted before.
Published online June 13, 2019.
Key...
Chronic lymphocytic leukemia treatment algorithm 2022
This 29 November 2022 review article published in the Blood Cancer Journal presents an...
Related Posts
- Health Canada approves Ibrutinib plus Rituximab for First Line Treatment of Patients with Chronic Lymphocytic Leukemia (CLL)
Dr. John Allan - Chronic Lymphocytic Leukemia (CLL) Patients @Undetectable Measurable Residual Disease (MRD) after Ibrutinib Plus Venetoclax
New research study reported in NEJM: Ibrutinib–Rituximab or Chemoimmunotherapy for Chronic Lymphocytic Leukemia- Efficacy of lenalidomide in relapsed/refractory chronic lymphocytic leukemia patient: a systematic review and meta-analysis
- First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.
